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Abstract
Background: In bipolar spectrum disorder, some individuals experience ongoing, frequent fluctuations in mood
outside of affective episodes. There are currently no evidence-based psychological interventions designed
to address this. This feasibility study is a phase II evaluation of a dialectical behavioural therapy-informed
approach (Therapy for Inter-episode mood Variability in Bipolar [ThrIVe-B]). It seeks to examine the feasibility
and acceptability of a future definitive trial evaluating the clinical and cost effectiveness of the ThrIVe-B
programme.
Methods/design: Patients will be randomised 1:1 to either treatment as usual only (control arm) or the ThrIVe-B
intervention plus treatment as usual (intervention arm). Follow-up points will be at 3, 6, 9 and 15 months after baseline,
with 9 months as the primary end point for the candidate primary outcome measures. We aim to recruit 48 individuals
meeting diagnostic criteria for a bipolar spectrum disorder and reporting frequent mood swings outside of acute
episodes, through primary and secondary care services and self-referral. To evaluate feasibility and acceptability,
we will examine recruitment and retention rates, completion rates for study measures and feedback from participants
on their experience of study participation and therapy.
Discussion: Proceeding to a definitive trial will be indicated if the following criteria are met: (1) trial participation does
not lead to serious negative consequences for our participants; (2) any serious concerns about the acceptability and
feasibility of the trial procedures can be rectified prior to a definitive trial; (3) follow-up data at 9 months are available
for at least 60% of participants; (4) at least 60% of patients in the ThrIVe-B arm complete treatment.
Trial registration: ISRCTN, ISRCTN54234300. Registered on 20 July 2017.
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Background
Bipolar disorders (BDs; comprising bipolar II and II dis-
order and cyclothymic disorder) are associated with con-
siderable personal costs, including increased risk of
premature death and of suicide [1]. The societal eco-
nomic cost is also high: In 2007, BDs cost the United
Kingdom around £5.2 billion [2], with the cost to the
UK Health Service (NHS) estimated at £342 million at
2009/10 prices [3].
Ongoing, frequent fluctuations in mood (henceforth
referred to as bipolar mood instability [BPMI]) can
occur across days and weeks for some individuals. This
pattern is characteristic of cyclothymic disorder, in
which individuals experience multiple periods of hypo-
manic and depressive symptoms with relatively little
time free from symptoms, but it is also experienced by
individuals with BD I or II outside of acute episodes of
mania or depression [4]. Presence of mood instability is
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a risk factor for future mania or depression, as well as
being associated with elevated rates of anxiety disorders,
substance use and difficulties in functioning [5–8].
Despite its prognostic importance, there is no gold
standard pharmacological strategy for BPMI, and relatively
few pharmacological treatment trials focus primarily upon
it as a feature of BDs [9, 10]. Established psychological
therapies for BD, including cognitive behavioural therapy,
focus upon ameliorating depression or preventing major
relapse [11], not upon addressing mood instability, which
is typically not even measured in trials of these therapies.
A small number of published studies have investigated
psychological therapies for cyclothymic disorder [12–14]
or have considered mood instability within a psychological
approach for individuals with BD [15, 16]; however, none
have selected those with BPMI across the bipolar
spectrum and tested an intervention that directly targets
this aspect. Consequently, we sought to develop an inter-
vention that addresses mood instability in all of those with
a bipolar spectrum condition who view this part of their
condition as a primary problem.
Dialectical behaviour therapy (DBT) [17] was initially de-
veloped for individuals with borderline personality disorder,
a patient group who also typically experience ‘stable in-
stability’ of mood. Several studies have examined modified
versions of DBTas an intervention for full BD, with encour-
aging results [18–21]; however, these have not specifically
selected those with mood instability, nor have they mea-
sured this as an outcome. Standard DBT targets key psy-
chological and interpersonal processes hypothesised to
contribute to mood instability related to negative emotion
(e.g., anger, sadness), but it does not discuss, or equip pa-
tients to manage, the hypomanic mood states present in bi-
polar spectrum conditions. Consequently we adapted
standard DBT to take this into account. Our approach (the
Therapy for Inter-episode mood Variability in Bipolar
[ThrIVe-B] programme) targets not only factors known to
precipitate or maintain full bipolar episodes (e.g., routine
disruption) [22] but also those likely to exacerbate frequent
mood swings (e.g., impulsive responding to minor mood
changes, including emerging hypomanic states) [23], as well
as some of the consequences of BPMI (e.g., relationship
problems, social avoidance and shame) that can act as fur-
ther sources of stress. Our treatment is informed by our
clinical experience with individuals with BPMI, by current
theory and evidence regarding basic psychological pro-
cesses that maintain mood instability, and by input from in-
dividuals with lived experience of BD.
In an initial open feasibility study (n = 12) we found
the ThrIVe-B approach to be acceptable to participants,
with 75% of participants who commenced the therapy
completing it (Wright, Palmer, Javaid, Mostazir & Lynch
T: Psychological Therapy for Mood Instability within
Bipolar Spectrum Disorder: Open Feasibility Trial of a
Dialectical Behaviour Therapy-Informed Approach, in
preparation). The approach was viewed as broadly ac-
ceptable by participants, with the majority describing
positive changes in symptoms, functioning or well-being
which they attributed to the programme. This in con-
junction with the pattern of clinical change observed
supported further investigation of this approach. To do
so, we propose a feasibility trial to resolve uncertainties
in trial design and delivery, including the feasibility of
running the trial across additional study sites, and to fur-
ther refine the content and delivery of the intervention.
To provide comprehensive information for a future trial,
multi-method evaluation is required, including measure-
ments of clinical outcome, cost-effectiveness and process
evaluation.
Objectives
We have the following objectives in this trial:
1. To establish recruitment pathways and trial teams
in two trial sites
2. To inform the recruitment and timeline of a future
fully powered trial by establishing the number of
participants initially identified, approached,
consented, randomised and completed
3. To refine future trial procedures by establishing the
acceptability and experience of the trial process to
participants, including randomisation and
completion of outcome measures
4. To further assess the acceptability of the treatment
via qualitative interviews and, based on input from
trial participants and clinicians, to further refine
and develop the treatment manual and the
procedures for training, supervising and assessing
the competence of trial therapists
5. To determine the optimal primary outcome
measure in a future trial by assessing the
performance of selected candidate primary
outcome measures with respect to level of
acceptability to participants (completion rates,
perceived burden) and participant-perceived rele-
vance and value
6. To inform estimation of sample size for a future
trial by measuring data completeness at follow-up
(participant attrition), SD of the likely primary out-
come measure, and the variability of the compara-
tor condition, treatment as usual (TAU), across
individuals and sites
7. To pilot a measure of resource use and to assess the
feasibility and acceptability of candidate health
economics measures to inform the future definitive
trial
8. To identify, measure and cost the resources needed
to deliver the intervention
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We will also evaluate whether the following continu-
ation criteria have been met prior to planning a future
definitive trial:
1. Trial participation does not lead to serious negative
consequences (unexpected serious adverse reaction)
for our participants.
2. Any serious concerns about the acceptability and
feasibility of the trial procedures can be rectified
prior to a full trial.
3. Follow-up data at 9 months are available for at least
60% of participants.
4. At least 60% of patients in the intervention group
complete treatment (attend at least 50% of possible
sessions).
Methods/design
This protocol is reported according to the Standard
Protocol Items: Recommendations for Interventional
Trials (SPIRIT) 2013 statement (see Additional file 1 for
the completed SPIRIT checklist).
Design
We will conduct a feasibility study with a two–arm, ran-
domised, parallel, controlled trial design. Participants
will be randomised in a 1:1 ratio to TAU only (control
arm) or TAU plus the ThrIVe-B programme (interven-
tion arm). Outcome measures will be recorded at base-
line and at four follow-up points—3, 6, 9 and 15 months
after randomisation—with 9 months as the primary end
point and the point of qualitative interview (because all
participants will have completed treatment by this
point).
Setting and participants
We will conduct the trial across two sites in the United
Kingdom. Participants will be recruited from primary
care services, secondary care mental health services and
via self-referral. Eligible participants will be aged 18
years or older and have a lifetime diagnosis of BD (I, II,
other specified BD) or cyclothymic disorder, according
to the Diagnostic and Statistical Manual of Mental Dis-
orders, Fifth Edition (DSM-V) [24], criteria. Within this,
they must have experienced at least a 2-day period in
which symptom criteria for hypomania were met during
their lifetime. They must report current BPMI, defined
as per DSM-V criteria 1 and 2 for cyclothymic disorder,
or by a score of 1.3 on the bipolar subscale of the short
form of the Affective Lability Scale (ALS; the mean score
on this subscale from previous research with individuals
with BD) [6]. They must also be willing to engage in psy-
chological therapy that focusses primarily on ongoing
mood instability and its consequences, and they must be
willing and able to attend the group therapy sessions as
scheduled. Participants must have sufficient competency
in English to be able to complete study measures with-
out the need for translation and be registered with a
general practitioner (GP) practice in the catchment area
served by the NHS trusts involved in the study. They
must not have current substance dependence, be receiv-
ing other psychological therapy for BD, or lack capacity
to consent to treatment or research participation. Partic-
ipants experiencing an acute manic or depressive epi-
sode (according to DSM-V), engaging in frequent,
significant self-harming behaviour, at high risk of suicide,
or posing a significant risk to other group members will
not be eligible for the study. This study locates the
ThrIVe-B programme at the interface between primary
and secondary care; therefore, participants must not be
receiving ongoing co-ordinated care in secondary mental
health services.
Neither medication status nor presence of co-morbid
psychiatric conditions will serve as exclusion criteria,
but this information will be recorded. In neither condi-
tion will participants be denied access to routine care,
nor will they be excluded from the study if they com-
mence psychological therapy as part of routine care,
after the point of randomisation.
Sample size
A total of 48 participants (24 per group) will allow us to
address the stated objectives of this feasibility trial. This
represents recruitment to three ThrIVe-B groups at full
capacity (8 per group), with equivalent numbers rando-
mised to TAU. On the basis of our previous work on the
ThrIVe-B programme, we estimate an attrition rate of
17% with respect to the primary end point at 9 months
post-randomisation. Our sample size of 48 will allow us
to estimate this level of attrition for a future definitive
trial with a precision of ±15% with 95% certainty and
allow us to estimate the SDs for any potential primary
outcome measures that would inform the power calcula-
tion for a definitive trial.
Randomisation, concealment of allocation, and blinding
Eligible participants will be randomised in a 1:1 ratio,
with minimisation by trial site and medication status. To
ensure concealment, eligible participants will be rando-
mised via a validated password website hosted by the
Exeter Clinical Trials Unit. The first ten participants will
be allocated using simple randomisation, the remainder
being allocated using the minimisation procedure, main-
taining a stochastic element to the algorithm to allow
concealment to be maintained. Following randomisation
of a given participant, he or she will be informed of their
allocation by an unblinded member of the research
team.
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Researchers conducting follow-up assessments will be
blind to study arm allocation and will remind partici-
pants of the need to conceal their allocation. We will
test blindness by asking researchers to indicate at
follow-up which treatment they believe the participants
received and analyse any correlation with outcome. We
will maintain the blinding as far as possible to maintain
the quality and legitimacy of the trial and its findings;
however, in the unlikely event that a participant has an
adverse reaction to either treatment arm, unblinding
may occur. We will unblind the researchers only in ex-
ceptional circumstances when the knowledge of the
treatment arm is deemed essential to the management
of the patient by their GP (e.g., serious adverse events).
Any unblinding that occurs will be recorded; where pos-
sible, researchers who remain blind to participant status
will conduct their future follow-up assessments. All stat-
istical analyses will be performed by a statistician using
groups indicated by an anonymised code.
Recruitment
Potential participants recruited from NHS providers
(through routine appointments or via phone or letter
contact) will be invited to complete a ‘permission to
contact’ form that includes information about the study
and gives agreement for the research team to contact
the individual. Within GP practices electronic case re-
cords will be searched by a member of practice staff,
using appropriate read codes followed by case note
search as needed, and eligible patients will be sent the
permission to contact form.
The study will also be advertised more widely to encour-
age self-referral, including through lists of people inter-
ested in research held by the University of Exeter and
University of Lancaster, posters in public areas, social and
traditional media, and promotions by relevant charities.
Following an expression of interest, patients referred
by a secondary care clinician will be sent full study infor-
mation and invited to attend a baseline assessment inter-
view in person. Those not referred by a secondary care
clinician, and thus who may not have had a comprehen-
sive mental health assessment prior to referral, will first
be invited to undergo a telephone screening call with a
member of the research team, after giving consent for
this step of the study. At the baseline assessment inter-
view researchers will take written informed consent,
confirm eligibility and collect baseline measures, some
of which will be completed by participants in their own
time after the interview. Eligible, fully informed and con-
senting participants will then be entered into the study.
Trial interventions
The ThrIVe-B programme has been developed iteratively
in consultation with ThrIVe-B patients and others with
personal experience of BDs. It follows five key principles
of DBT: (1) clearly structured treatment; (2) application
of behavioural therapy; (3) emphasis on validation of
emotional response; (4) dialectical stance, balancing ac-
ceptance and change; and (5) integration of mindfulness
practice. Topics covered include skills for observing
events, thoughts, emotions and bipolar symptoms with-
out reacting impulsively; balancing lifestyle and activities
to maximise mood stability and healthy rather than
hypomanic positive mood; and skills for down-regulating
emotion, problem-solving and negotiating interpersonal
difficulties (which are often a consequence and a trigger
of bipolar mood swings). As is standard DBT practice
ThrIVe-B emphasises the importance of participants
learning skills through teaching and practice, having op-
portunities to generalise these skills across real-world
contexts, and continuing use of skills beyond treatment
end. This will be achieved structurally through a com-
bination of group meetings (15, held weekly) and up to 8
concurrent fortnightly individual sessions of up to
45 min delivered in person or by telephone.
To enhance real-life generalisation of skills, partici-
pants in the ThrIVe-B arm will be given a custom-built
smartphone application (‘app’) which alerts participants
to rate their mood level at random points each day
(number of daily alerts determined by user). Handsets
can be borrowed by participants without their own.
When mood is above or below user-determined ‘high’
and ‘low’ mood thresholds, a feedback screen appears
containing advice pre-entered by the user, which can in-
clude skills learned in the ThrIVe-B programme. A ver-
sion of this app, with reduced functionality, will be used
to monitor mood variability in real time over 7-day pe-
riods at baseline and at follow-up for all participants.
In addition there will be an optional supporters’ group
meeting (midway through the series of group meetings)
during which friends or relatives can attend and learn
about the skills covered, enabling them to better support
the participant with use of these. To support the gener-
alisation and ongoing adoption of skills beyond the acute
treatment, patients will be invited to attend a group
‘reunion’ booster session at 3 months after therapy.
ThrIVe-B therapists will be psychological therapists with
a background in either cognitive behavioural therapy or
DBT. Training for the ThrIVe-B programme will be a
5-day course. Assuming participants’ consent, therapy ses-
sions will be taped and recordings used to develop fidelity
and competency measures for use in a definitive trial. Re-
cordings will also be used to inform weekly supervision
sessions during the active treatment phase. Participants
will complete the Beck Depression Inventory [25] and Alt-
man Scale for Rating Mania [26] prior to each group ses-
sion, and the scores will be used to inform their care, as
well as forming part of the research data collected.
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Our comparison arm is ‘usual care’. This is because
there is currently no gold standard psychological treat-
ment for this client group against which to benchmark a
new treatment. There are no formal data to indicate the
likely content of TAU for individuals with BPMI across
the United Kingdom; thus, we will record this in terms
of the services received by each participant during the
trial in order to characterise the variability of TAU
within and between study sites, based upon responses to
the resource use questionnaire. No restrictions will be
placed on the content of TAU, other than the study
entry criterion which excludes individuals currently re-
ceiving psychological therapy for BD.
Outcomes
We will conduct follow-up assessments at 3, 6, 9 and
15 months after baseline, with the 3- and 6-month as-
sessments being conducted via post or online, and the 9-
and 15-month assessments including a face-to-face or
telephone interview.
Primary outcome measures
Feasibility will be assessed in terms of numbers of pa-
tients identified, approached, consented, randomised and
completed over the active period of recruitment and
treatment, as well as participant attrition from the trial
and from treatment. As part of feasibility and acceptabil-
ity analyses we will assess whether the continuation rules
stated previously have been met.
To assess acceptability all participants will complete a
questionnaire about their experience in the trial, including
ranking candidate primary outcome measures at 9-month
follow-up in terms of their perceived personal value and
relevance, and a subset of 12 participants will be invited to
take part in a semi-structured interview to allow more de-
tailed exploration of their experiences of both the research
study and the treatment. Sampling will be purposive and
will include participants from across the two trial arms
and trial sites to facilitate understanding of the potential
impact of differential therapy and trial contexts. It will also
seek to include individuals who did, and who did not,
complete treatment and study assessments. Participants
who exit the study at any point in the process will be in-
vited to complete a brief survey of their reasons for exit-
ing, and experiences of the trial so far.
As part of the study, referring clinicians will be asked
to take part in the process evaluation, giving their views
of the therapy and research process via a brief survey
form. In addition, ThrIVe-B therapists will be invited to
take part in an interview asking about their experiences
and views of the therapy and associated training follow-
ing the end of their involvement in the intervention
phase. Patient adherence to treatment will be indexed by
the number of therapy sessions attended.
Secondary outcome measures
Participants will complete the following measures at
baseline and all follow-up points, representing candidate
primary outcome measures for a future definitive trial:
the Patient Health Questionnaire 9-item scale [27],
which measures depressive symptoms; the ALS [28]; the
Bipolar Disorder Recovery Questionnaire [29]; and the
Quality of Life in Bipolar Disorder scale [30]. Partici-
pants will also complete the Generalised Anxiety Dis-
order 7-item scale [31]. At baseline, 9 and 15 months,
the Bech Mania Rating Scale [32], the Hamilton Depres-
sion Rating Scale [33] (both observer-rated), and the
Brief Adherence Rating Scale for medication adherence
[34] will be completed, as will relevant sections of the
Structured Clinical Interview for DSM-V [35] to as-
sess both eligibility criteria, and presence of affective epi-
sodes during the follow-up period.
In addition, participants will complete the EuroQoL
5-dimension 5-level (EQ-5D-5L) instrument [36] and
the 36-item Short Form Health Survey [37] in order to
assess how feasible it is to use these measures in this
population. This will allow us to identify potential rea-
sons for incomplete data. In the future randomised con-
trolled trial, the scores will be used to obtain utility
values for deriving quality-adjusted life-years in order to
estimate incremental cost-effectiveness ratio. Partici-
pants will be asked also to complete a resource use
questionnaire (last 6 months or since last assessment
point) to assess the feasibility of collecting health and
social service use. Information on the resource use and
costs of delivering the ThrIVe-B programme will be
collected.
Quantitative process measurement
To inform process measurement in a definitive trial,
measures of hypothesised mechanisms of change will be
included, providing data on their performance and ac-
ceptability to participants. Hypothesised treatment tar-
gets include mood-related impulsivity, avoidance and
interpersonal functioning (Positive and Negative Ur-
gency, Premeditation, Perseverance, Sensation-Seeking
impulsive behaviour scales [38]; Behavioral Activation in
Depression Scale [39]), emotional acceptance and mind-
fulness skills (Kentucky Inventory of Mindfulness Skills
[40]), emotional problem solving (Means-Ends Problem
Solving task [41]) and social rhythm stability (adapted
Social Rhythm Metric [42]).
Experience sampling
Experience sampling will be carried out using the
purpose-built ThrIVe-B app to gather data on mood
variability in real time. This is a potential secondary out-
come in a definitive trial; therefore, in the current trial
we wish to test the feasibility and acceptability of
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gathering these data within both arms of the trial,
assessed by return rates and participant feedback. Partic-
ipants will be invited to use the app for 1 week at base-
line and at 9-month follow-up. In addition, the app, with
additional functionality enabled, will be used by those in
the ThrIVe-B + TAU arm as part of treatment, as de-
scribed previously. In order that those in the TAU arm
rate over a period similar to that in the ThrIVe-B arm,
and in order that mood variability data are available
from both groups over the treatment period of the study,
those in the TAU arm will be prompted to use the app
at month 3, until month 9. The version they use will not
contain the therapeutic elements (namely specifying a
threshold and pre-programming feedback); instead they
will simply be able to select the number of mood rating
alerts per day and rate mood.
Participant ranking of outcome measures
In order to gather information on patient-valued out-
comes at the 9-month follow-up point, participants will
be asked to rank measures to reflect their personal prior-
ities with respect to areas in which they would want to
see change following a treatment: depression symptoms,
anxiety symptoms, mood changes, sense of personal re-
covery and quality of life.
Procedure
Following the initial eligibility assessment and comple-
tion of baseline measures, including 7 days of experience
sampling using the app, participants will be invited to
complete follow-up assessments at 3, 6, 9 and 15 months
after baseline, with an additional 7 days of experience
sampling at the 9-month point. Assessments will be in
person (face to face or by telephone), by post or online,
dependent upon patient preference, with in-person con-
tact required at months 9 and 15 in order to complete
the interview-based measures. Figure 1 (SPIRIT figure)
displays the measures completed at each time point.
At month 9, in addition to completing the set of mea-
sures, participants will be asked to rank them. Also at
month 9, a subset of participants will be invited to take
part in a semi-structured interview about their experi-
ences of the trial with an unblinded member of the re-
search team.
Data analysis
Quantitative data analysis
Patients’ demographic characteristics at baseline will be
reported by treatment group. The primary analyses will
be performed after 9-month follow-up and after data
cleaning is completed and the database finalised. Further
analyses will be performed after the final 15-month
follow-up. No interim analyses are planned.
All analyses will be done on an intention-to-treat basis;
included outcomes will be reported according to rando-
mised allocation and regardless of the treatment actually
received. There will be no possibility of participants allo-
cated to the control arm receiving the intervention; it is
possible that participants allocated to the intervention
will in actuality receive none of the intervention or will
not complete the intervention (defined as attendance of
at least 50% of group sessions). All outcomes will be re-
ported descriptively. At 9-month follow-up only, an in-
ferential analysis will be performed for continuous
outcomes only, reporting the relevant 95% CI for the
between-group mean difference (intervention minus
TAU), but no p value. Inferential analyses will include
the randomisation covariates: site and baseline medica-
tion status. No interactions between intervention status
and covariates are planned.
Proportions of participants recruited (of those
approached) and those lost to follow-up at 3, 6, 9 and
15 months, will be reported with 95% CIs. All analyses
will use complete case data only. No attempts to address
missing data, such as multiple imputation, will be made.
The economic analysis will take the NHS and social care
perspective. No covariate analysis or subanalysis will be
conducted, because this is a feasibility trial and is not pow-
ered for such inferential analyses. Descriptive data for each
arm will be reported with CIs for between-group compari-
sons. No p values will be reported.
Qualitative analysis
In keeping with process evaluation guidance from the
Medical Research Council (MRC) [43], the process evalu-
ation of this feasibility study will focus upon facilitators
and barriers to implementation of the intervention in
order to inform implementation of the intervention within
a future definitive trial. It will also evaluate the acceptabil-
ity and feasibility of the trial process itself to inform the
conduct of a future definitive trial. Within these, following
the framework recommended in the MRC guidance, we
will consider the impact of context (how external factors
may have influenced the delivery and functioning of the
intervention, and here also the trial process) and imple-
mentation (evaluation of the way in which the interven-
tion is delivered, and the quality and quantity of the
intervention delivered, including fidelity, dose and reach).
In addition we will tentatively explore potential mech-
anisms of impact (how the intervention might bring
about its effects, in interaction with the participants)
qualitatively, to refine our current working logic model.
Finally, and related to implementation, we will gather
preliminary data on the long-term feasibility of this
intervention within the NHS [44] through feedback
gathered from referrers and therapists.
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Qualitative interviews will be analysed using a frame-
work approach [45], whereby data will be coded accord-
ing to both theme and case, and then abstraction of
themes and explanatory inferences will occur iteratively
with codes, themes and inferences being quality-checked
by a second team member.
Data management and storage
Information in the form of routine clinical notes, mea-
sures and therapy recordings will be stored according to
standard practice within the NHS service hosting the
intervention. Hard copies of information/measures gath-
ered as part of this research study will be anonymised
and stored in a locked filing cabinet in a locked office in
the Department of Psychology, University of Exeter, or
the Spectrum Centre, University of Lancaster. Hard cop-
ies of data collected during assessments at the second
study site may be stored temporarily and securely on
NHS Trust premises before being transferred to Lancas-
ter University. Consent forms will be stored separately
from data, and data will be anonymised wherever pos-
sible. Data will be double-entered on a secure,
web-based system maintained by the Clinical Trials Unit,
University of Exeter.
The datasets generated during and/or analysed during
the current study will be stored in a non-publicly
Enrolment Allocation Study Period Close-out
TIMEPOINT -3 to 0 months 0 3 6 9 15
18-26 
months 
ENROLMENT:
Eligibility screen X
Informed consent X
Completion of 
baseline measures X
Allocation X
Follow-up 
measures X X X X
Qualitative 
Interviews X
Analysis, 
dissemination, 
archiving.
X
INTERVENTIONS:
Usual care
ThrIVe-B 
programme
ASSESSMENTS:
Symptom 
measures (PHQ9, 
GAD7, BRMS, 
HAMD, ALS
X X X X X
Quality of life / 
recovery measures 
(QoL.BD, BDRQ)
X X X X X
Candidate process 
measures (UPPS-
P, BADS, KIMS, 
MEPS, SRM)
X X X X X
Health Economic 
Measures (Service 
use inventory, EQ-
X X
X
(servi
ce 
X X
5D-5L, SF36) use 
only)
Medication use 
measure
X X
Experiencing 
sampling 
(smartphone app)
X X
Fig. 1 Schedule of enrolment, interventions and assessments (displayed according to Standard Protocol Items: Recommendations for Interventional
Trials [SPIRIT] template)
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available repository within the University of Exeter fol-
lowing completion of the trial. Anonymised data may be
accessed and analysed by members of the project team
and with researchers collaborating with members of the
project team on the analysis of these data. With the ex-
ception of anonymised quotes from research interviews,
consent from participants was not sought for sharing
raw data publicly. Therefore, external researchers seek-
ing to access the data for use in future projects must do
so via request to the chief investigator (or her delegate),
and projects using the data must have been approved in
accordance with contemporary UK ethical and regula-
tory processes pertaining to the release of anonymised
data under these circumstances.
Original research records will be retained for 7 years,
after which they will be retained in electronic form and
original records destroyed, including records of partici-
pant names and contact details, and audio files of
semi-structured interviews (which will be retained only
in transcribed form). The electronic records will be kept
for 20 years after the end of the study. Published mater-
ial will not contain patient-identifiable information.
Study approvals
The conduct of the trial will be in accordance with the
Helsinki declaration. The study has received approval
from the UK National Research Ethics Service and the
Health Research Authority (IRAS ID 219816) and from
all relevant local approval bodies.
Anticipated risks and benefits
Because of the inclusion of a comparison arm in which
participants receive TAU, participants will have only a
50% chance of receiving the ThrIVe-B programme. Par-
ticipants will be fully informed of this aspect of the trial
and the reasons for it. No aspect of standard care will be
withheld as a result of trial participation. Through par-
ticipating in this trial, participants will receive an en-
hanced level of monitoring by the research team, and
where suicidal risk or significant worsening of their
mental state is detected, they will be directed to appro-
priate care, in accordance with established protocols in
the relevant research centres and clinical services.
The study seeks to test a novel intervention. This is an
adaptation of a well-established treatment (DBT), as ap-
plied to a population that differs in some ways from the
main recipient population. There are four published
studies reporting pilot trials of DBT with individuals
with BD (in adolescents and adults), all with favourable
results [18–21]. Our approach does not differ from these
in essence, but it includes some adaptations relevant to
the particular subgroup question and is tailored to a UK
context. In an open trial of the ThrIVe-B programme
[24], there were no unexpected serious adverse reactions
to the therapy.
The participant information sheets will describe pos-
sible benefits and risks of taking part. The research team
will inform participants if any new information comes to
light that has a bearing upon their safety as a participant
in the trial.
Individuals with bipolar spectrum disorders are at in-
creased risk of suicide compared with the general popu-
lation. We will follow established clinical and research
protocols for monitoring and responding to suicide risk
during therapy and research contacts. The participant
information sheet will inform participants of the possi-
bility that confidentiality could be broken where serious
risk to an individual is detected; wherever possible, re-
sponses to elevated risk will be made with the partici-
pant’s knowledge and agreement.
Adverse events
All serious adverse events that are trial- or treatment-related
will be recorded and immediately reported to the chief inves-
tigator and trial sponsor. If these are also classed as unex-
pected they will be reported to the NRES committee. We
will, in line with other complex intervention studies, monitor
non-serious adverse events, serious adverse events that are
not trial- or treatment-related, serious deterioration, and ac-
tive withdrawals from treatment. Adverse events will include
any events for which the participant consulted their GP or
other medical advisor or for which the participant took new
or additional medication. Symptoms of BD or cyclothymic
disorder themselves are not defined as adverse events. Data
on any adverse events will be collected by a member of the
research team at each assessment through screening of
health service use; therapists will also report any adverse
events reported by participants to the trial team. Instances
where participants report suicidal ideation that requires
information-sharing action by the research team, according
to the study risk management protocol, will be counted as
adverse events.
Criteria for discontinuation
There are two levels of discontinuation for participants
in the ThrIVe-B arm: A participant may discontinue
therapy but remain in the trial, or they may discontinue
the trial. If a participant in either arm indicates at any
point that they wish to discontinue the trial they will not
be contacted further by the research team, other than to
invite them to take part in a brief written survey to as-
certain their reasons for not taking part. If a participant
does not attend more than three consecutive group ther-
apy sessions this will generally be judged to indicate dis-
continuation of therapy, as will the participant opting to
discontinue at any point.
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Individual participants will be discontinued from the
trial if they experience a serious adverse reaction that is
judged to be the direct result of the intervention or trial
participation, or if the participant, the therapist, or the
research team believes that the intervention or trial par-
ticipation will result in, or is likely to result in, a serious
adverse reaction if continued.
Should an unexpected serious adverse reaction occur
to either the therapy or the trial procedures, and if this
is judged to be directly related to trial participation or to
the therapy, the trial will be temporarily halted pending
investigation and analysis of the extent to which future
risk can be mitigated. If it is judged that this is not pos-
sible, the trial will be discontinued. This process will be
led by the sponsor in collaboration with the TSC chair
and chief investigator. The same process will be followed
should information come to light that indicates that the
therapy intervention or trial procedures are unsafe.
Patient and public involvement
We developed the ThrIVe-B programme with input
from the patient and public involvement (PPI) group at
the University of Exeter Mood Disorders Centre (Lived
Experience Group [LEG]), who advised on the content
and form of the intervention. We then gathered detailed
feedback from participants as part of our open trial of
the programme. This feedback led to changes to the
intervention in terms of both content and delivery,
resulting in the intervention to be evaluated in the
current study. This feedback also shaped the trial proce-
dures we propose for this study. Our open trial also in-
cluded obtaining feedback from referring NHS clinicians
both before and after intervention delivery.
Our current trial protocol was developed with input
from two members of the LEG. The ThrIVe-B trial team
includes a PPI lead. With the chief investigator, this indi-
vidual has convened and chairs a PPI reference group who
oversee PPI strategy and operation for the trial. They also
edit participant-facing research and therapy materials,
consult on the conduct of the trial, and contribute to the
dissemination strategy. We follow national good practice
with regard to remuneration of PPI representatives.
Trial governance
A trial steering committee (TSC), independent from the
sponsor, has been convened, including independent
members (academic and clinical) as well as the principal
investigator and trial statistician, and will meet approxi-
mately five times over the life of the project. The TSC
will be responsible for advising the trial team on the
conduct of the study. Given the relatively small scale of
the trial a separate data monitoring and ethics commit-
tee (DMEC) will not be convened. Instead the DMEC
functions (reviewing data collected including adverse
events and making recommendations for the future con-
duct of the trial) are included within the terms of refer-
ence of the TSC. For all substantive changes to the
protocol approval will be sought from the sponsor and
the relevant national regulatory bodies.
Role of the funder and sponsor
The sponsor has ultimate authority over the management
of the study. Neither the funder nor the sponsor of the
study was involved in the design of the study and will not
be involved in the collection, analysis or interpretation of
data or the writing of the study report. The funder will be
required to approve the final report prior to publication.
Dissemination
Findings will be disseminated both at a local level, to partic-
ipants, services and other stakeholders, and at a national/
international level through conference presentations and
publication of findings in a peer-reviewed journal in open
access form. Findings will also be disseminated through
media and social media where possible. The dissemination
strategy will be informed by the trial PPI reference group.
Discussion
This trial is designed to assess the feasibility and accept-
ability of a randomised controlled trial of a DBT-informed
psychological intervention for individuals with BPMI in
primary care. The findings will inform future investigation
of this approach, potentially in the form of a definitive
randomised controlled trial testing its clinical effectiveness
and cost-effectiveness.
Trial status
The start date of the trial was 6 June 2017. Recruitment
ran from July 2017 to July 2018. Follow-up will last 15
months, with the entire study period lasting 29 months.
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Additional file 1: SPIRIT 2013 checklist: ThrIVe-B study*. (DOC 121 kb)
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